Half-year report · Q2
4588.TEDINET S100WI59
Period2025-01-01 → 2025-06-30
Filed2025-08-08
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥29m | 2025-01-01 → 2025-06-30 | Standalone | Net sales |
| Revenue | ¥31m | 2024-01-01 → 2024-12-31 | Standalone | Net sales (5-year summary) |
| Revenue | ¥31m | 2024-01-01 → 2024-06-30 | Standalone | Net sales |
| Operating income | −¥1.3bn | 2025-01-01 → 2025-06-30 | Standalone | Operating income |
| Operating income | −¥793m | 2024-01-01 → 2024-06-30 | Standalone | Operating income |
| Ordinary income | −¥1.3bn | 2025-01-01 → 2025-06-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.7bn | 2024-01-01 → 2024-12-31 | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥753m | 2024-01-01 → 2024-06-30 | Standalone | Ordinary income |
| Profit before tax | −¥1.3bn | 2025-01-01 → 2025-06-30 | Standalone | Income before income taxes |
| Profit before tax | −¥753m | 2024-01-01 → 2024-06-30 | Standalone | Income before income taxes |
| Net income | −¥1.3bn | 2025-01-01 → 2025-06-30 | Standalone | Profit loss |
| Net income | −¥1.7bn | 2024-01-01 → 2024-12-31 | Standalone | Net income loss (5-year summary) |
| Net income | −¥755m | 2024-01-01 → 2024-06-30 | Standalone | Profit loss |
| Total assets | ¥1.9bn | at 2025-06-30 | Standalone | Assets |
| Total assets | ¥3.2bn | at 2024-12-31 | Standalone | Assets |
| Total assets | ¥1.9bn | at 2024-06-30 | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥493m | at 2025-06-30 | Standalone | Liabilities |
| Total liabilities | ¥447m | at 2024-12-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.4bn | at 2025-06-30 | Standalone | Net assets |
| Net assets / equity | ¥2.8bn | at 2024-12-31 | Standalone | Net assets |
| Net assets / equity | ¥1.4bn | at 2024-06-30 | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.4bn | at 2025-06-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.4bn | at 2024-12-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.1bn | at 2025-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2024-12-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥872m | at 2024-06-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥1.3bn | at 2023-12-31v | Standalone | Cash and cash equivalents |
| Operating cash flow | −¥1.0bn | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥2.0bn | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.1bn | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in operating activities |
| Investing cash flow | −¥5m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥5m | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in investment activities |
| Financing cash flow | ¥42m | 2025-01-01 → 2025-06-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥2.9bn | 2024-01-01 → 2024-12-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥686m | 2024-01-01 → 2024-06-30 | Standalone | Net cash provided by used in financing activities |
| EPS (basic) | ¥-52.85 | 2025-01-01 → 2025-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-77.17 | 2024-01-01 → 2024-12-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-36.96 | 2024-01-01 → 2024-06-30 | Standalone | Basic earnings loss per share (5-year summary) |
| Equity ratio | 74.1% | at 2025-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.8% | at 2024-12-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 74.7% | at 2024-06-30 | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 24,961,600 | at 2025-06-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,961,600 | at 2024-12-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 20,961,600 | at 2024-06-30 | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 434
| Item | Context | Value | Unit |
|---|---|---|---|
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)権利内容に何ら限定のない当社における標準となる株式 | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)オンコリスバイオファーマ株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都港区虎ノ門４丁目１-28 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Type1 semi annual financial statements financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Description of fact that consolidated financial statements have not been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Quarterly statement of cash flows (text) | CurrentYTDDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding dividend (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration_NonConsolidatedMember | Text · Plus | |
| Notes equity in earnings losses of affiliates if equity method is applied quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Description of fact that companys business comprises single segment | Prior1YTDDuration_NonConsolidatedMember | Original text (Japanese)当社は、創薬事業の単一セグメントであるため、記載を省略しております。 | |
| Description of fact that companys business comprises single segment | CurrentYTDDuration_NonConsolidatedMember | Original text (Japanese)当社は、創薬事業の単一セグメントであるため、記載を省略しております。 | |
| Notes revenue recognition quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |